Target intelligence / Profile preview

Marburg virus glycoprotein - Niemann-Pick C1 receptor binding site (MARV GP-NPC1 RBS)

Target
MARV GP-NPC1 RBS
Molecular classification
Viral glycoprotein, Host-pathogen interface, Receptor binding site
01

Overview

The Marburg virus glycoprotein (MARV GP) - Niemann-Pick C1 (NPC1) receptor binding site is a critical molecular junction required for the entry of Marburg virus into host cells. The viral GP is a trimeric surface protein that, upon internalization into host endosomes, undergoes proteolytic processing by host cathepsins to remove the glycan cap and mucin-like domain, thereby exposing the receptor binding site (RBS) on the GP1 subunit (Hashiguchi et al., 2015, Cell). This exposed RBS specifically binds to the luminal domain C of NPC1, a host intracellular cholesterol transporter that serves as an obligatory entry receptor for all known filoviruses (Carette et al., 2011, Nature; Ng et al., 2012, eLife). This binding event is the prerequisite for the subsequent conformational changes in the GP2 subunit that drive the fusion of viral and endosomal membranes. Because the GP-NPC1 interaction is a conserved and mandatory step in the viral life cycle, it represents a high-priority target for the development of antiviral therapies, such as monoclonal antibodies (e.g., MR191) and small-molecule inhibitors designed to block viral attachment and entry (King et al., 2018, Cell Reports). Targeting this site aims to block the viral entry process, thereby preventing the progression of Marburg virus disease, a severe and often fatal hemorrhagic fever.

Other names
Marburg marburgvirus glycoprotein - NPC1 receptor binding siteMARV GP-NPC1 interfaceMarburg virus GP receptor binding domainMARV GP1-NPC1 binding siteMarburg virus glycoprotein RBS
02

Mechanism of action

The mechanism of action involves the competitive or steric inhibition of the binding between the primed (cathepsin-cleaved) Marburg virus glycoprotein 1 (GP1) subunit and the second luminal domain (Domain C) of the host Niemann-Pick C1 (NPC1) receptor. By preventing this interaction, the drug blocks the subsequent GP2-mediated membrane fusion, thereby halting the entry of the viral ribonucleoprotein into the host cell cytoplasm (Hashiguchi et al., 2015, Cell; Ng et al., 2012, eLife).

03

Biological functions

Viral entryReceptor bindingMembrane fusionEndosomal escape
04

Disease associations

Marburg virus diseaseViral hemorrhagic feverInfection
05

Safety considerations

Viral mutational escapePotential disruption of host cholesterol transport (if targeting NPC1)Requirement for endosomal delivery of therapeutics
06

Interacting drugs

MR191

2 more in the full profile.

07

Biomarkers

Marburg virus RNA loadAnti-MARV GP antibody titersSoluble glycoprotein (sGP) levels

Beyond the preview

Go deeper on Marburg virus glycoprotein - Niemann-Pick C1 receptor binding site (MARV GP-NPC1 RBS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marburg virus glycoprotein - Niemann-Pick C1 receptor binding site (MARV GP-NPC1 RBS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call